Made by Paris-based drugmaker Ipsen, the new therapy, irinotecan liposome, known by its brand name Onivyde, is an injection that the FDA now recommends being administered through infusion every two weeks. The infusion process takes about 90 minutes total.
During the phase 3 trial, which included 770 patients, Onivyde extended longevity for patients who took it regularly by a median survival length of 11.1 months versus just 9.2 months of survival for patients who received other treatments.
Adverse outcomes were rare and the most common side effects for patients involved in the trial were fatigue, nausea, vomiting, decreased appetite, abdominal pain and diarrhea.
Onivyde was designated by the FDA to be an “orphan drug”, which is not necessarily profitable, but a drug created for treatment of patients with rare conditions.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
